Back to today’s briefing

Story perspectives

Omeros Shares Surge 146% on $2.1 Billion Deal

10/15/2025

32 4 Full Breakdown

Summary

Story summary

Omeros Corporation (NASDAQ: OMER) shares jumped about 146% to around $10.11 on October 15, 2025, after a licensing agreement with Novo Nordisk A/S for zaltenibart (OMS906) valued up to $2.1 billion.
The deal includes a $340 million upfront payment and future milestones.
Novo Nordisk plans to initiate a global Phase 3 trial of zaltenibart for rare blood and kidney diseases.
Novo Nordisk's shares remained stable after the announcement.

History

Historical Context

In 2025, Omeros Corporation's $2.1 billion licensing agreement with Novo Nordisk A/S highlighted the pharmaceutical industry's growing focus on rare disease treatments. This mirrors the 2014 partnership between Gilead Sciences and Pharmasset, which transformed hepatitis C care. Such collaborations reflect a significant shift towards innovative therapies, reshaping investment strategies and management in the pharmaceutical sector.

1 of 2

Story summary

Omeros Corporation (NASDAQ: OMER) shares jumped about 146% to around $10.11 on October 15, 2025, after a licensing agreement with Novo Nordisk A/S for zaltenibart (OMS906) valued up to $2.1 billion.
The deal includes a $340 million upfront payment and future milestones.
Novo Nordisk plans to initiate a global Phase 3 trial of zaltenibart for rare blood and kidney diseases.
Novo Nordisk's shares remained stable after the announcement.

1 / 2